Biologic targeting interferon signaling
Anifrolumab
Can help selected adults with active lupus, targeting a different immune pathway from belimumab.
Select a heading to expand or collapse.
Why might it be prescribed?
May be added to standard care after an assessment of disease activity and organ involvement.
What makes this medicine different?
Not every biologic is appropriate for every lupus manifestation, especially when organ disease calls for specialist regimens.
Explore the topics that matter to you
How it works: analogy and explanation
It binds to the type I interferon receptor, blocking a group of related signals.
The analogy is a learning aid, not a literal description of biology.
How is it used and when may it help?
Administration depends on the approved product and plan; IV infusion or subcutaneous options may be available by jurisdiction and formulation. Do not assume products are interchangeable.
If you miss a dose, follow the instructions for your specific product or ask your pharmacist. Do not double up without explicit advice.
Side effects and monitoring
Respiratory infections and injection or infusion-related symptoms may occur.
Discuss infection history, shingles and vaccinations before treatment.
Which medicines may interact?
Vaccines, especially live vaccines, and concurrent immune suppressants need specialist review. Do not combine biologics yourself.
These are important examples, not a complete interaction list. Some combinations are intentional with monitoring; others may need avoidance. Bring your complete medicine list to your appointments.
Pregnancy, breastfeeding and family planning
Pregnancy data are limited; plan with your specialist.
When to get prompt or urgent medical help
Significant fever, painful blistering rash or breathing difficulty needs prompt assessment.
How does it compare with other medicines?
Teach-back: explain in your own words
Think through your answer before expanding the review notes. Nothing is recorded or sent.
Someone thinks anifrolumab and belimumab are identical because both are biologics. How would you explain the difference?
(+) Show review points
Both affect immune messages, but anifrolumab blocks type I interferon signaling while belimumab reduces a B-cell survival signal.
Sources and clinical review status
- U.S. National Library of Medicine, MedlinePlus patient drug monograph. Read original monograph
- American College of Rheumatology (ACR). 2025 Lupus Treatment Guideline summary. Read guideline
- Fanouriakis A, et al. EULAR recommendations for SLE: 2023 update. Ann Rheum Dis. 2024;83:15–29. Read source
Last editorial update: 11 October 2026.
Clinical review: Educational draft; documented clinical review and sign-off pending. Not represented as clinically approved.
Editorial method: Plain-language explanation checked against drug monographs and lupus guidelines; examples do not replace individual medical advice.
Some monographs list approved uses other than lupus; specialist lupus use may follow clinical guidelines. External resources are in English.